US

Provivi snags $85 mln Series C

Provivi Inc, an emerging crop protection company, has raised $85 million in Series C financing. Pontifax Global Food and Agriculture Fund led the round.

Building Engines nabs $12.7 mln

Boston-based Building Engines, an operations platform for commercial real estate owners, operators and occupants, has raised $12.7 million in funding. Wavecrest Growth Partners led the round with participation from River Cities Capital Funds, MassMutual Ventures and Camber Creek Ventures.

German hybrid estate agent McMakler lands $20 mln

Berlin-based McMakler, a real estate platform, has raised $20 million in funding. The investors were Balderton Capital and GR Capital.

Algolia raises $110 mln

Algolia said Oct. 15 that it raised $110 million in funding led by existing investor Accel. Salesforce Ventures and other firms also participated. Algoria is a Search-as-a-Service platform.

Elsewhere Partners recruits Stephens as CTO

Elsewhere Partners has named Josh Stephens as chief technology officer. Stephens has been an adviser to the growth-stage venture firm since 2015.

Rho Business nets $4.9 mln seed

Rho Business, a New York-based digital business banking platform for high-growth companies, has raised $4.9 million in seed funding. Alexa Von Tobel of Inspired Capital led the round.

Abalos Therapeutics grabs Series A

Abalos Therapeutics, a German cancer drug developer, has raised 12 million euros in Series A financing. Boehringer Ingelheim Venture Fund and Gruenderfonds Ruhr led the round.

Azitra fetches $14 mln Series A

Farmington, Connecticut-based Azitra Inc, a clinical-stage medical dermatology company addressing serious skin conditions by harnessing the microbiome, has raised $14 million in Series A financing. KdT Ventures and Bios Partners led the round with participation from Connecticut Innovations and Godfrey Capital.

VHP promotes Fisher to partner

Varsity Healthcare Partners has promoted Michael Fisher to partner. Fisher joined the healthcare services-focused lower middle-market private equity firm in 2016.

Cyteir Therapeutics scores $40.2 mln Series B

Lexington, Massachusetts-based Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has secured $40.2 million in Series B funding. Novo Holdings led the round with participation from Venrock, DROIA Oncology Ventures, Osage University Partners, Lightstone Ventures and Celgene Corporation. As part of this closing, Dr. Karen Hong of Novo Ventures will join the Cyteir board.